The APOA1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of HeLa cells harboring disruption of the APOA1 gene, which encodes apolipoprotein A-I, the principal protein component of high-density lipoprotein (HDL). This knockout model is produced using CRISPR/Cas9-mediated gene disruption, generating a heterogeneous pool of cells with loss-of-function mutations at the target locus. The polyclonal format provides a robust and technically accessible resource for loss-of-function studies without the need for single-cell cloning, enabling efficient investigation of APOA1-dependent pathways in a widely used human cell line.
HeLa cells are an immortalized epithelial line derived from a HPV18-positive cervical adenocarcinoma, characterized by functional inactivation of the tumor suppressors p53 and Rb through viral oncoproteins E6 and E7. Their robust growth kinetics, ease of transfection, and extensive molecular characterization have established HeLa as a cornerstone cell model in biomedical research, suitable for studies ranging from cell signaling to host-pathogen interactions.
APOA1 mediates key steps in reverse cholesterol transport by interacting with ATP-binding cassette transporter A1 (ABCA1) to promote cholesterol efflux from peripheral cells, and activating lecithin-cholesterol acyltransferase (LCAT) to esterify cholesterol on nascent HDL particles. This process is transcriptionally regulated by liver X receptors LXR??/?? (NR1H3/NR1H2) and peroxisome proliferator-activated receptor ?? (PPAR??), which form heterodimers with retinoid X receptor ?? (RXR??) and respond to insulin, thyroid hormone, and estrogen. Downstream, APOA1 facilitates cholesterol delivery to the liver via scavenger receptor class B type I (SR-BI)-mediated selective uptake and cholesteryl ester transfer protein (CETP)-mediated lipid exchange. Additionally, APOA1-associated HDL particles carry paraoxonase 1 (PON1) and myeloperoxidase (MPO), linking lipoprotein metabolism to anti-inflammatory and antioxidant responses, particularly in macrophages through PI3K/AKT signaling.
In HeLa cells, genetic deletion of APOA1 abrogates the cell’s capacity to produce and secrete functional apolipoprotein A-I, rendering them deficient in HDL-mediated cholesterol efflux and LCAT activation. Given that HeLa cells are of epithelial origin and possess active lipid metabolism, this knockout model is particularly valuable for dissecting the intracellular and paracrine roles of APOA1 in cholesterol homeostasis and inflammatory signaling independent of liver-specific factors. The well-defined cancer background also permits exploration of how HDL-related pathways intersect with oncogenic signaling in HPV-driven malignancies.
This polyclonal knockout cell population is suited for various research applications, including studies of HDL biogenesis, reverse cholesterol transport, and foam cell formation using cholesterol efflux assays and lipid profiling by mass spectrometry. It enables screening of compounds that modulate APOA1-dependent cholesterol handling or LCAT activity, and facilitates investigation of upstream regulators such as LXR and PPAR?? agonists through RT-qPCR and immunoblotting. Additional applications include co-culture experiments to assess the anti-inflammatory properties of HDL on macrophages, and functional assays evaluating APOA1 interactions with ABCA1, SR-BI, and CETP by immunofluorescence or biochemical approaches. For further information, please contact Ascent Research.
